Opinion|Videos|June 25, 2024
ADRIATIC Trial: Durvalumab, cCRT Timing, and Survival in LS-SCLC
Panel experts analyze findings from the phase 3 ADRIATIC trial, examining overall and progression-free survival data, exploring the interaction between durvalumab and concurrent chemoradiotherapy within the tumor microenvironment, and evaluating the impact of time intervals from the completion of concurrent chemoradiotherapy to the initiation of consolidation therapy with a PD-L1 inhibitor.
Advertisement
Episodes in this series
- Please discuss results from the phase 3 ADRIATIC trial, evaluating durvalumab in patients with LS-SCLC who did not have disease progression following concurrent chemoradiotherapy (cCRT) vs placebo after cCRT. (
Spigel D, et al. Plenary Session 2024 ASCO Annual Meeting. LBA5. ) - How might the statistically significant overall survival and progression-free survival outcomes reported in ADRIATIC translate to clinically relevant improvement in life expectancy of your patients with limited-stage SCLC?
- What are the mechanisms by which durvalumab synergizes with concurrent chemoradiotherapy within the tumor microenvironment?
- In patients with LS-SCLC, what would you consider to be a reasonable time interval between completion of cCRT to initiation of consolidation therapy with a PD-L1 inhibitor?
- Please discuss your thoughts on the range of time prior to initiating therapy - from immediately to 6 weeks post-cCRT.
- What is the potential for curative-intent immunotherapy with durvalumab for earlier stages of SCLC?
- What is the role of SBRT in earlier stages of disease vs cCRT followed by durvalumab?
Advertisement
Related to this article
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.
Eric K. Singhi, MD, and Kyle G. Mitchell, MD, MSc, discuss the present and future role of LCT in NSCLC.
Millie Das, MD, outlines how maintenance tarlatamab and lurbinectedin may extend survival beyond current 3-year OS rates in ES-SCLC.
Top experts discuss the most important takeaways and data to come out of this year’s ASCO Annual Meeting in non–small cell lung cancer.
The DLL3-targeting antibody-drug conjugate zocilurtatug pelitecan received FDA orphan drug designation for the management of neuroendocrine carcinomas.
A growing clinical phenomenon of incidentally finding early-stage lung cancer suggests a significant gap in the current screening paradigm.
Experts go step by step in laying out their thought processes and treatment selections for difficult-to-treat lung cancer cases.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to BI-1808 Plus Pembrolizumab in Ovarian Cancer
2
FDA Grants Accelerated Approval to RP1 Plus Nivolumab for Advanced Melanoma After Anti–PD-1 Therapy
3
The OncFive: Top Oncology Articles for the Week of 8/2
4
Sonrotoclax Is Active in Chinese R/R MCL Cohort of the BGB-11417-201 Trial
5